Effect of Mirogabalin on Chemotherapy-Induced Peripheral Neuropathy Caused by Gemcitabine plus Nab-Paclitaxel Therapy in Pancreatic Cancer Patients: A Pilot Study
Journal of Vascular Diseases · 2022
DOI: 10.3390/jvd1010005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Vascular Diseases, 2022. Verfasst von Yusuke Takasaki und 10 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Gemcitabine/nab-paclitaxel therapy (GnP) is widely used to treat pancreatic cancer (PC), but chemotherapy-induced peripheral neuropathy (CIPN) is common. The CIPN is also reported to be related by microvascular damage as the basis for toxic neuropathy. However, no sufficient treatment options are available for CIPN. Mirogabalin is a novel drug for treating peripheral neuropathy. We investigated the effects of mirogabalin on CIPN due to GnP.
Methods
Patients who had received GnP for PC and had taken mirogabalin for CIPN, were included. Patients completed a questionnaire about their symptoms before and after taking mirogabalin. The outcome was the change in numbness and tingling scores on the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy (EORTC-QLQ-CIPN20), numerical rating scale, and adverse events (AEs).
Results
Increased numbness and tingling severity (1.84 vs. 1.76; p = 0.63) and interference (1.42 vs. 1.44; p = 0.80) were not seen in any of the 25 enrolled patients. The scores on the sensory subscale of the EORTC-QLQ-CIPN improved significantly after treatment (17.5 vs. 15.7; p = 0.02). Adverse events occurred in 22 patients (88%), but there were no serious AEs (≥grade 3).
Conclusions
Mirogabalin may control the progression of CIPN caused by GnP and significantly improved sensory neuropathy. However, as the incidence of AEs is high, mirogabalin should be used with caution. (UMIN:R000044039).
Zitieren
APA
Takasaki, Y., Fujisawa, T., Ushio, M., Takahashi, S., Yamagata, W., Suzuki, A., Ito, K., Ochiai, K., Tomishima, K., Ishii, S., & Isayama, H. (2022). Effect of Mirogabalin on Chemotherapy-Induced Peripheral Neuropathy Caused by Gemcitabine plus Nab-Paclitaxel Therapy in Pancreatic Cancer Patients: A Pilot Study. Journal of Vascular Diseases. https://doi.org/10.3390/jvd1010005
Vancouver
Takasaki Y, Fujisawa T, Ushio M, Takahashi S, Yamagata W, Suzuki A, et al. Effect of Mirogabalin on Chemotherapy-Induced Peripheral Neuropathy Caused by Gemcitabine plus Nab-Paclitaxel Therapy in Pancreatic Cancer Patients: A Pilot Study. Journal of Vascular Diseases. 2022. doi:10.3390/jvd1010005
BibTeX
@article{Takasaki2022,
author = {Takasaki, Yusuke and Fujisawa, Toshio and Ushio, Mako and Takahashi, Sho and Yamagata, Wataru and Suzuki, Akinori and Ito, Koichi and Ochiai, Kazushige and Tomishima, Ko and Ishii, Shigeto and Isayama, Hiroyuki},
title = {Effect of Mirogabalin on Chemotherapy-Induced Peripheral Neuropathy Caused by Gemcitabine plus Nab-Paclitaxel Therapy in Pancreatic Cancer Patients: A Pilot Study},
journal = {Journal of Vascular Diseases},
year = {2022},
doi = {10.3390/jvd1010005}
}
EUVIMED